GBM (glioblastoma) is a difficult-to-treat, aggressive cancer that can occur in the brain or spinal cord. Current therapy consists primarily of surgical resection of the tumor, followed by radiation and chemotherapy. More than 50% of patients with GBM express one or more oncogenic EGFR alterations. While EGFR inhibitors have not shown efficacy in these patients, we believe that those failures are due to multiple liabilities in prior compounds — all of which are addressed by BDTX-1535.

BDTX-1535 has recently completed a Phase 1 trial in recurrent GBM, and promising topline data were disclosed in 2023.

BDTX-1535 is currently in a "window of opportunity" trial for 2nd-line GBM patients. Learn more at clinicaltrials.gov.